Clinical Trial Update: Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risankizumab to placebo in psoriasis patients in the Russian Federation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED